GNI Group Ltd
TSE:2160
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 544
3 805
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
GNI Group Ltd
GNI Group Ltd
Income from Continuing Operations
GNI Group Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GNI Group Ltd
TSE:2160
|
Income from Continuing Operations
¥5.3B
|
CAGR 3-Years
58%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
PeptiDream Inc
TSE:4587
|
Income from Continuing Operations
¥17.1B
|
CAGR 3-Years
40%
|
CAGR 5-Years
46%
|
CAGR 10-Years
64%
|
|
|
Takara Bio Inc
TSE:4974
|
Income from Continuing Operations
¥942m
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-5%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Income from Continuing Operations
¥3.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
100%
|
CAGR 10-Years
N/A
|
|
|
S
|
StemRIM Inc
TSE:4599
|
Income from Continuing Operations
-¥2B
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Income from Continuing Operations
-¥632.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
Glance View
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
See Also
What is GNI Group Ltd's Income from Continuing Operations?
Income from Continuing Operations
5.3B
JPY
Based on the financial report for Sep 30, 2024, GNI Group Ltd's Income from Continuing Operations amounts to 5.3B JPY.
What is GNI Group Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
49%
Over the last year, the Income from Continuing Operations growth was 47%. The average annual Income from Continuing Operations growth rates for GNI Group Ltd have been 58% over the past three years , 49% over the past five years .
You don't have any saved screeners yet
